NCT01587807View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

March 28, 2012

Primary Completion Date

November 19, 2012

Study Completion Date

November 19, 2012

Conditions
Respiratory Disorders
Interventions
DRUG

GSK1995057

inhaled dose (volume based on cohort)

PROCEDURE

bronchoalveolar lavage

BAL

DRUG

LPS

50 μg

DRUG

Placebo

Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)

Trial Locations (2)

BT9 6AD

GSK Investigational Site, Belfast

HA1 3UJ

GSK Investigational Site, Harrow

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY